Guangdong Marubi Biotech announced plans to issue H-shares and list on Hong Kong’s Main Board. The A-share cosmetics company aims to enhance capital strength and overseas financing capability while accelerating business internationalization. The company reported Q1-Q3 2025 revenue of 2.45 billion RMB ($338 million), up 25.51% YoY, though net profit grew only 2.13% to 244 million RMB ($33.6 million). Management noted significant price increases across product categories, particularly in eye care products which rose 54.77%. The Hong Kong listing will complete within 24 months of shareholder approval.